Moderna (NASDAQ:MRNA – Get Free Report)‘s stock had its “sector perform” rating reaffirmed by stock analysts at Royal Bank of Canada in a research report issued on Tuesday,Benzinga reports. They ...

As bad as it may look on the charts, Moderna’s (NASDAQ: MRNA) post-COVID let-down and market reset are over. The company ...

We recently published a list of 10 Firms Kick Off Shortened Trading Week With Impressive Gains. In this article, we are going ...

Barclays downgraded shares of Moderna (NASDAQ:MRNA – Free Report) from an overweight rating to an equal weight rating in a report published on Tuesday, Ratings reports. The firm currently has $45.00 ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

Financially, Barclays noted that Moderna’s revenue declined sharply. Fourth-quarter SpikeVax sales came in at $923 million, below Barclays’ estimate of $1.087 billion, and total 2024 product revenue ...

Despite a significant revenue decline, Moderna Inc (MRNA) focuses on strategic program prioritization and cost management to ...

The Dow fell and the Nasdaq Composite rose Nasdaq Friday as the stock market reacted to news of delays to President Donald Trump's reciprocal tariffs.

Live updates on stocks, bonds and other markets, including the Dow Jones Industrial Average, S&P 500 and Nasdaq Composite.

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

Moderna shares fell 3% in premarket trading after the biotech company swung to a quarterly loss, as fading demand for its Covid-19 vaccine hurts sales. The company reported a net loss of $1.1 billion, ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...